🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseDoctor said my fatty liver is GONE - I literally cried — my results so far Page 2

Doctor said my fatty liver is GONE - I literally cried — my results so far

cory_ATX Sun, Feb 23, 2025 at 1:03 AM 8 replies 1,546 viewsPage 2 of 2
mike_nyc
VIP Member
5,678
21,345
Nov 2023
New York
Online
Feb 23, 2025 at 6:52 AM#6
MikeFit_NJ said:
Liver enzyme update related to liver and MASH: I had mildly elevated ALT/AST at baseline (likely NAFLD).

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
16 11maya_sedona, stefan_berlin, Dr.EM_Chicago and 13 others
Reply Quote Save Share Report
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Feb 23, 2025 at 9:09 AM#7
cory_ATX said:
Fatty liver on an incidental scan two years ago and nobody followed it up.

Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 320 dB/m (moderate steatosis) and stiffness 10.8 kPa (possible fibrosis). Diagnosed with NAFLD.

After 12 months: CAP dropped to 243 dB/m (minimal steatosis) and stiffness normalized to 5.6 kPa. Hepatologist says the liver is essentially healing itself as the metabolic stress resolves.

GLP-1 agonists may become first-line NASH therapy. The Phase 3 data on semaglutide for NASH is very promising.

15 10hank_denver, carlos_SATX, sophie_paris and 12 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Feb 23, 2025 at 11:26 AM#8
mike_nyc said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Coming at mike_nyc’s question from a different direction. It is worth asking what the claim would look like if it were false. If nothing would look different, it is not a claim about the world and no amount of discussion will settle it.

14 9maya_sedona, stefan_berlin, Dr.EM_Chicago and 11 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
rick_sfbay
Member
289
1,234
Jan 2025
San Francisco, CA
Feb 23, 2025 at 1:43 PM#9

A narrower follow-up, since the general answer is now clear:

How long did you give it before you decided it was working?

13 8FranDenver, Dr.BariatricHTX, LindaRN_retired and 10 others
Reply Quote Save Share Report
cory_ATX
Member
456
2,123
Jul 2024
Austin, TX
Feb 24, 2025 at 12:42 AM#10

OP back with an update, since a thread like this is useless without one.

Update, and it is the boring outcome: nothing was wrong. The measurement I was reading had moved less than its own week-to-week variation, which somebody said upthread and I did not believe.

23 21tane_welly, Dr.PathRoch, mona_PHX and 20 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register